Cystic Fibrosis – Epidemiology – Mature Markets
Clarivate’s Epidemiology’s coverage of cystic fibrosis (CF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the birth incidence and prevalence of CF for each country, as well as annualized case counts projected to the national population.
Clarivate’s Epidemiology’s CF forecast will answer the following questions:
- How will improvements in survival change the number of people living with a diagnosis of CF?
- Of all people diagnosed with CF, how many in each country are drug-treated?
- How will demographic trends, such as population aging and improving life expectancy, affect the epidemiology of CF over the forecast period?
All forecast data are available on the Clarivate’s Insights Platform in tabular format, with options to download to MS Excel. All populations are accompanied by a comprehensive description of the methods and data sources used, with hyperlinks to external sources. A summary evidence table generated as part of our systematic review of the epidemiological literature is also provided for full transparency into research and methods.
Clarivate’s Epidemiology forecasts the following CF patient populations:
- Birth incident cases.
- Diagnosed prevalent cases.
- Diagnosed prevalent cases stratified by CFTR mutation.
- Diagnosed prevalent cases stratified by FEV1 status.
- Diagnosed prevalent cases stratified by airway pathogen.
- Drug-treated prevalent cases.
Note: Coverage may vary by country.
Table of contents
- Cystic Fibrosis - Epidemiology - Mature Markets
- Epidemiology data
- Methods
- Literature review (studies included in/excluded from the analyses of cystic fibrosis)
- Birth incident cases
- Diagnosed prevalent cases
- Diagnosed prevalent cases stratified by CFTR mutation
- Diagnosed Prevalent Cases Stratified by FEV1 Status
- Diagnosed prevalent cases stratified by airway pathogen
- Diagnosed drug-treated prevalent cases
- Risk / protective factors applied to disease forecast models
- Reference materials
- Bibliography
- Glossary
- Abbreviations table
Jagriti Prasad, M.P.H., is an associate epidemiologist at Clarivate. Prior to joining the company, she worked on a research project exploring trends in a rare cancer and its subtype using data spanning 44 years in the largest cancer registry of northern England (NRYPMDR). She obtained her M.P.H. from Newcastle University in the United Kingdom and her B.D.S. from Manipal University in India.
Jackie Liu, M.P.H., Ph.D., Manager, Epidemiology. She first joined Clarivate as a Medtech analyst and worked on forecasting the global vascular devices market. She received her Ph.D. in molecular genetics and her M.P.H. in epidemiology from the University of Toronto in Canada.